<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443104</url>
  </required_header>
  <id_info>
    <org_study_id>065/11</org_study_id>
    <nct_id>NCT01443104</nct_id>
  </id_info>
  <brief_title>Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents</brief_title>
  <official_title>A Randomized Comparison of a Sirolimus-eluting Stent With Biodegradable Polymer Versus an Everolimus-eluting Stent With a Durable Polymer for Percutaneous Coronary Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery stents have improved the safety and efficacy of percutaneous coronary&#xD;
      intervention for coronary artery disease. Drug-eluting stents have been shown to decrease&#xD;
      neointimal hyperplasia and to reduce the rate of restenosis and target-lesion&#xD;
      revascularization as compared to bare-metal stents. Drug-eluting stents consist of a metallic&#xD;
      platform and a therapeutic substance that is usually released from a polymer matrix. A&#xD;
      previous study utilizing a bioresorbable polymer has demonstrated a favorable safety and&#xD;
      efficacy profile in a large-scale clinical trial as compared to a first-generation&#xD;
      druf-eluting stent (LEADERS trial).&#xD;
&#xD;
      The objective of the study is to compare the safety and efficacy of a sirolimus-eluting stent&#xD;
      with a biodegradable polymer with an everolimus-eluting stent with a durable polymer in a&#xD;
      prospective multicenter randomized controlled non-inferiority trial in patients undergoing&#xD;
      percutaneous coronary intervention in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Coronary artery stents have improved the safety and efficacy of percutaneous coronary&#xD;
      interventions compared with balloon angioplasty alone (New Engl J Med 1994; 331:489-495).&#xD;
      Notwithstanding, restenosis is still encountered in 20 to 30% of lesions after implantation&#xD;
      of bare metal stents (JAMA 2000; 284:1828-36) and may require repeat revascularization&#xD;
      procedures with a negative impact on quality of life and health care expenditures.&#xD;
      Drug-eluting stents with local, controlled release of therapeutic agents have addressed this&#xD;
      problem successfully (Circulation 2003; 107:3003-7). Current drug-eluting stents consist of a&#xD;
      metallic stent platform and a therapeutic agent, which is either directly immobilized on the&#xD;
      stent surface or released from a polymer matrix. Polymers currently utilized for drug-eluting&#xD;
      stents are either biodegradable or non-biodegradable. While biodegradable polymers are&#xD;
      released together with the drug and dissolve after a certain period of time,&#xD;
      non-biodegradable polymers reside permanently on the stent surface.&#xD;
&#xD;
      First-generation drug-eluting stents utilized sirolimus and paclitaxel for prevention of&#xD;
      restenosis. Both drugs are highly lipophilic and show rapid and strong uptake in arterial&#xD;
      wall tissue. In addition, Sirolimus (Circulation 2001; 104:852-5) and paclitaxel (Circulation&#xD;
      1997; 96:636-45) have been shown to reduce smooth muscle cell proliferation and neointimal&#xD;
      hyperplasia, the principal cause of restenosis after coronary stenting in experimental&#xD;
      models. A polymer-encapsulated stent releasing Sirolimus has been compared with the&#xD;
      respective bare metal stent in several randomized clinical trials, demonstrating a consistent&#xD;
      reduction in angiographic and clinical restenosis (N Engl J Med 2002; 346:1773-80).&#xD;
      Similarly, a polymer-based, paclitaxel-eluting stent consistently reduced restenosis and the&#xD;
      need for repeated revascularization procedures compared with the respective bare metal stent&#xD;
      (N Engl J Med 2004; 350:221-31). A meta-analysis of drug-eluting stent trials confirmed the&#xD;
      reduction in restenosis and repeat revascularization procedures for polymer-based,&#xD;
      drug-eluting stents (Lancet 2004; 364:583-91). Moreover, the rates of death and myocardial&#xD;
      infarction were comparable to those with bare metal stents, attesting to the safety of these&#xD;
      devices, which have been approved by the US Food and Drug Administration.&#xD;
&#xD;
      Newer generation drug-eluting stents with durable polymer coating utilize Limus analogues&#xD;
      such as everolimus, zotarolimus or novolimus. Everolimus-eluting stents have been compared to&#xD;
      first-generation drug-eluting stents in several randomized clinical trials. A pooled analysis&#xD;
      of the four largest randomized trials to date comparing everolimus-eluting stents with&#xD;
      paclitaxel-eluting stents demonstrated a lower rate of MACE (4.4% versus 7.6%), myocardial&#xD;
      infarction (2.1% vs. 4.0%, p&lt;0.001), ischemic TLR (2.3% vs. 4.7%, p&lt;0.001), and definite&#xD;
      stent thrombosis (0.4% vs. 1.2%, p&lt;0.001) in favor of EES, whereas there was no difference&#xD;
      with regard to overall and cardiac mortality (Stone GW. The XIENCE V - PROMUS&#xD;
      Everolimus-Eluting Stent: New Insights from the SPIRIT/COMPARE Meta-analysis and other&#xD;
      randomized trials. Presentation at Transcatheter Cardiovascular Therapeutics, September 22nd&#xD;
      2010). At the same time several trials comparing everolimus-eluting stents with&#xD;
      sirolimus-eluting stents reported favorable performance of everolimus-eluting stents. In a&#xD;
      randomized trial enrolling 2'774 patients everolimus-eluting stents were non-inferior&#xD;
      compared with sirolimus-eluting stents at nine months with regard to MACE (4.9% vs. 5.2%, HR&#xD;
      0.94, 0.67-1.31) and TLR (1.4% vs. 1.7%, HR 0.87, 0.48-1.58) (N Engl J Med&#xD;
      2010;362(28):1663-74). Likewise, event rates at two years were similar for everolimus-eluting&#xD;
      stents and sirolimus-eluting stents (3.7% versus 4.3%, p=0.85) in a randomized controlled&#xD;
      trial comparing EES, SES, and BMS in large vessels (stent diameter &gt;3.0 mm), whereas TVR was&#xD;
      lower with both EES (3.7%) and SES (4.3%) as compared with bare-metal stents (10.3%, P=0.005&#xD;
      vs SES, P=0.002 vs EES) (N Engl J Med 2010;363(24):2310-9). A propensity-score matched&#xD;
      comparison of EES and SES reported lower event rates of myocardial infarction (3.3% versus&#xD;
      5.0%, HR 0.62, 95% CI 0.42-0.92, P=0.017) in part due to a lower risk of stent thrombosis&#xD;
      (definite or probable 2.5% versus 4.0%, HR 0.64, 95% CI 0.41-0.98, P=0.041), as well as a&#xD;
      lower rate of target vessel revascularization (7.0% versus 9.6%, HR 0.75, 95% CI 0.57-0.99,&#xD;
      P=0.039) for EES at three years while mortality was similar (Windecker S. Long-term&#xD;
      comparison of Everolimus-eluting and Sirolimus-eluting Stents for coronary revascularization&#xD;
      1 (LESSON1) study. Presentation at the European Society of Cardiology meeting, Stockholm,&#xD;
      Sweden, 31st August 2010. 2010).&#xD;
&#xD;
      A previous study utilizing a bioresorbable polymer has demonstrated a favorable safety and&#xD;
      efficacy profile in a large-scale clinical trial as compared to a first-generation&#xD;
      drug-eluting stent. Among 1,707 patients randomized to either a biolimus-eluting stent with a&#xD;
      bioresorbable polymer or a sirolimus-eluting stent with a durable polymer no significant&#xD;
      differences with regard to the primary endpoint of cardiac death, myocardial infarction or&#xD;
      target-vessel revascularization were observed (9.2% versus 10.5%, HR 0.88, 95% CI 0.64-1.19;:&#xD;
      p=0.39)(Lancet 2008;372:1163-73.)&#xD;
&#xD;
      Objective&#xD;
&#xD;
      The objective of the study is to compare the safety and efficacy of a sirolimus-eluting stent&#xD;
      with a biodegradable polymer with an everolimus-eluting stent with a durable polymer in a&#xD;
      prospective multicenter randomized controlled non-inferiority trial in patients undergoing&#xD;
      percutaneous coronary intervention in routine clinical practice.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Design: Prospective, multi-center, randomized, non-inferiority trial. Patients will be&#xD;
      randomized in a single-blind fashion (1:1 randomization) to either the Orsiro® Stent system&#xD;
      (Sirolimus-eluting stent with a biodegradable polymer) with the Xience PRIME® stent system&#xD;
      (Everolimus-eluting stent with a durable polymer).&#xD;
&#xD;
      Primary endpoint: Target lesion failure (TLF), defined as the composite of cardiac death,&#xD;
      target vessel myocardial infarction (MI), and clinically driven target-lesion&#xD;
      revascularization (TLR).&#xD;
&#xD;
      Inclusion Criteria: &quot;Real world, all comer&quot; patients with symptomatic coronary artery disease&#xD;
      including patients with chronic stable angina, silent ischemia, and acute coronary syndromes&#xD;
      including NSTE-ACS and STE-ACS, and presence of one or more coronary artery stenoses &gt;50% in&#xD;
      a native coronary artery or a saphenous bypass graft which can be treated with a stent&#xD;
      ranging in diameter from 2.25 to 4.0 mm and can be covered with one or multiple stents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure (TLF), defined as the composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) and emergent coronary artery bypass grafting (CABG)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with target lesion revascularization (TLR)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with target lesion revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with target lesion revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with target lesion revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated and not clinically indicated target vessel revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated and not clinically indicated target vessel revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated and not clinically indicated target vessel revascularization (TVR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated and not clinically indicated target vessel revascularization (TVR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave and NQWMI)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave and NQWMI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave and NQWMI)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave and NQWMI)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave and NQWMI)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2119</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Orsiro Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting Stent with a Biodegradable Polymer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience Prime Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting Stent with a Durable Polymer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)</intervention_name>
    <description>Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease</description>
    <arm_group_label>Orsiro Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent with a durable polymer</intervention_name>
    <description>Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease</description>
    <arm_group_label>Xience Prime Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Symptomatic coronary artery disease including patients with chronic stable angina,&#xD;
             silent ischemia, and acute coronary syndromes including NSTE-ACS and STE-ACS&#xD;
&#xD;
          -  Presence of one or more coronary artery stenoses &gt;50% in a native coronary artery or a&#xD;
             saphenous bypass graft which can be treated with a stent ranging in diameter from 2.25&#xD;
             to 4.0 mm and can be covered with one or multiple stents&#xD;
&#xD;
          -  No limitation on the number of treated lesions, and vessels, and lesion length&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known intolerance to aspirin, clopidogrel, heparin, stainless steel, Sirolimus,&#xD;
             Everolimus or contrast material&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Currently participating in another trial before reaching first endpoint&#xD;
&#xD;
          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained&#xD;
             throughout the peri-surgical period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Windecker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Bern University Hospital, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFR Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de cardiologie CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Franzone A, Eberli F, Jüni P, Windecker S, Pilgrim T. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. J Am Heart Assoc. 2016 Mar 15;5(3):e003255. doi: 10.1161/JAHA.116.003255.</citation>
    <PMID>26979080</PMID>
  </results_reference>
  <results_reference>
    <citation>Franzone A, Pilgrim T, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Räber L, Stortecky S, Wenaweser P, Jüni P, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. Circ Cardiovasc Interv. 2015 Jun;8(6). pii: e002319. doi: 10.1161/CIRCINTERVENTIONS.114.002319.</citation>
    <PMID>26043895</PMID>
  </results_reference>
  <results_reference>
    <citation>Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blöchlinger S, Wenaweser P, Jüni P, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. EuroIntervention. 2016 Dec 10;12(11):e1343-e1354. doi: 10.4244/EIJY15M12_09.</citation>
    <PMID>26690319</PMID>
  </results_reference>
  <results_reference>
    <citation>Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1.</citation>
    <PMID>25189359</PMID>
  </results_reference>
  <results_reference>
    <citation>Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Muller O, Moarof I, Siontis GCM, Cook S, Weilenmann D, Kaiser C, Cuculi F, Hunziker L, Eberli FR, Jüni P, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018 Sep 1;392(10149):737-746. doi: 10.1016/S0140-6736(18)31715-X. Epub 2018 Aug 28.</citation>
    <PMID>30170848</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>drug-eluting stents</keyword>
  <keyword>polymers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

